Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials

Conclusion: Interobserver agreement using DS in DLBCL patients in I-PET and EoT-PET yields high OA and NA. The lower PA suggests that EoT-PET/CT treatment evaluation in daily practice and I-PET–adapted trials may benefit from dual reads and central review, respectively.

Source: Journal of Nuclear Medicine - December 3, 2018 Category: Nuclear Medicine Authors: Burggraaff, C. N., Cornelisse, A. C., Hoekstra, O. S., Lugtenburg, P. J., De Keizer, B., Arens, A. I. J., Celik, F., Huijbregts, J. E., De Vet, H. C. W., Zijlstra, J. M., on behalf of the HOVON Imaging Working Group Tags: Clinical Source Type: research